menu
    • menu
    [{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"RPESC-RPE-4W","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Luxa Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ California Institute for Regenerative Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Luxa Biotechnology

    Menu

    Luxa Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Luxa Biotechnology

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Luxa Biotechnology

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Luxa Awarded $4M Grant to Support Clinical Trial for Macular Degeneration Therapy

                            Details : The grant from CIRM supports the ongoing early-stage clinical trials involving RPESC-RPE-4W transplantation for treating dry age-related macular degeneration.

                            Brand Name : RPESC-RPE-4W

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 01, 2024

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth